Veru Inc's third quarter 2026 EPS loss of $0.30 beat estimates as enobosarm trial enrollment exceeded targets

Veru reported a narrower-than-anticipated net loss for its third quarter of fiscal 2026, although revenue was effectively non-existent as the company continues its pivot from product sales to clinical drug development. The company prioritized capital toward the Phase 2b PLATEAU trial of enobosarm, which reached full enrollment during the period, while general and administrative costs were reduced significantly compared to the prior year.

Key Highlights

• The Phase 2b PLATEAU clinical trial for high-quality weight loss reached full enrollment with 239 patients, exceeding the initial 200-patient target.
• Research and development expenses were $4.4 million, representing a substantial decrease from the $11.2 million analyst expectation despite accelerated clinical activity.
• Cash and cash equivalents reached $23.9 million as of June 30, 2026, up from $15.8 million at the end of fiscal 2025.
• The USPTO issued a notice of allowance for a key patent covering the combination of enobosarm and semaglutide, extending intellectual property protection until 2044.